Who should sponsor sleep disorders pharmaceutical trials?
作者信息
Kripke Daniel F
出版信息
J Clin Sleep Med. 2007 Dec 15;3(7):671-3.
Abstract
摘要
相似文献
1
Who should sponsor sleep disorders pharmaceutical trials?
J Clin Sleep Med. 2007 Dec 15;3(7):671-3.
2
Eszopiclone: an update on its use in insomnia.
Drugs Today (Barc). 2011 Apr;47(4):263-75. doi: 10.1358/dot.2011.47.4.1590792.
3
In brief: lowering the dose of Lunesta.
Med Lett Drugs Ther. 2014 Jun 9;56(1444):48.
4
Drug-induced hemichorea.
BMJ Case Rep. 2015 May 20;2015:bcr2014208872. doi: 10.1136/bcr-2014-208872.
5
Possibility that certain hypnotics might cause cancer in skin.
J Sleep Res. 2008 Sep;17(3):245-50. doi: 10.1111/j.1365-2869.2008.00685.x.
6
Hypnotics and skin cancer: hint at drug carcinogenesis, coincidence, or benefit of more sleep?
J Sleep Res. 2008 Sep;17(3):243-4. doi: 10.1111/j.1365-2869.2008.00695.x.
7
Greater incidence of depression with hypnotic use than with placebo.
BMC Psychiatry. 2007 Aug 21;7:42. doi: 10.1186/1471-244X-7-42.
8
A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
Sleep Med. 2012 Dec;13(10):1247-53. doi: 10.1016/j.sleep.2012.08.015. Epub 2012 Oct 11.
9
Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.
Sleep. 2009 Jun;32(6):817-24. doi: 10.1093/sleep/32.6.817.
10
Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
Hum Psychopharmacol. 2008 Jul;23(5):385-97. doi: 10.1002/hup.936.
引用本文的文献
1
Advances in the management of insomnia.
F1000Prime Rep. 2014 Jun 2;6:48. doi: 10.12703/P6-48. eCollection 2014.
2
Diagnosis and treatment of chronic insomnia.
Ann Indian Acad Neurol. 2010 Apr;13(2):94-102. doi: 10.4103/0972-2327.64628.
3
Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem.
J Clin Sleep Med. 2009 Aug 15;5(4):377-83.
本文引用的文献
1
Benzodiazepine use and mortality of incident dialysis patients in the United States.
Kidney Int. 2007 Dec;72(11):1388-93. doi: 10.1038/sj.ki.5002548. Epub 2007 Sep 12.
2
Greater incidence of depression with hypnotic use than with placebo.
BMC Psychiatry. 2007 Aug 21;7:42. doi: 10.1186/1471-244X-7-42.
3
The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs.
J Gen Intern Med. 2007 Sep;22(9):1335-50. doi: 10.1007/s11606-007-0251-z. Epub 2007 Jul 10.
4
Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study.
Sleep. 2007 Jun;30(6):743-52. doi: 10.1093/sleep/30.6.743.
5
Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
Clin Gastroenterol Hepatol. 2006 Dec;4(12):1445-51. doi: 10.1016/j.cgh.2006.08.019. Epub 2006 Nov 13.
6
Relationship between drug company funding and outcomes of clinical psychiatric research.
Psychol Med. 2006 Nov;36(11):1647-56. doi: 10.1017/S0033291706008567. Epub 2006 Aug 8.
7
Drug trials: stacking the deck.
Nature. 2006 Mar 16;440(7082):270-2. doi: 10.1038/440270a.
8
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.
BMJ. 2005 Nov 19;331(7526):1169. doi: 10.1136/bmj.38623.768588.47. Epub 2005 Nov 11.
9
National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005.
Sleep. 2005 Sep;28(9):1049-57. doi: 10.1093/sleep/28.9.1049.
10
Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry.
Am J Psychiatry. 2005 Oct;162(10):1957-60. doi: 10.1176/appi.ajp.162.10.1957.
Zotero 插件